Global Microbiome Therapeutics (Additive, Modulatory, Subtractive) Market, 2020-2026 with Profiles of Azitra, Evelo Biosciences, LNC Therapeutics, Second Genome and Vedanta Biosciences
The global market for microbiome therapeutics should grow from $141.7 million in 2021 to $1.3 billion by 2026, at a compound annual growth rate (CAGR) of 56.4% for the period of 2021-2026.
GIT diseases market for microbiome therapeutics should grow from $87.9 million in 2021 to $222 million by 2026, at a CAGR of 20.4% for the period of 2021-2026.
Infections diseases market for microbiome therapeutics should grow from $53.8 million in 2021 to $191.8 million by 2026, at a CAGR of 28.9% for the period of 2021-2026.
This report provides a comprehensive analysis of the microbiome therapeutics market in global context, including market forecasts and sales through 2025.
The report analyzes the market by segmenting it into the various types of microbiome therapeutics, based on the strategies used for treatment: additive (fecal matter transplants or FMTs, live biotherapeutic products or LBPs), modulatory (postbiotics, prebiotics) and subtractive microbiome therapeutics (phages and antimicrobials).
The Human Microbiome Project (HMP), MetaHIT and other independent efforts fueling the exploration of microbiome and its association with human health have led to a research explosion in this area in the last decade. Myriad of studies abound that show that microbiome has a role in mediating many physiological processes such as metabolism, nutrition and immunity.
It has been observed in many clinical studies that alterations in the microbial populations or microbial dysbiosis can lead to diseases. As such, modulations of the microbiome such that its normal condition is restored or pathogenic bacteria is eliminated have become potential strategies to address many unmet medical needs. Diseases that still do not have any definitive cure, or available treatments are either not satisfactory or costprohibitive, are being actively targeted as treatment indications by microbiome therapeutics.
There are many active players in the field of microbiome therapeutics, ranging from discovery and clinical-stage to late-stage companies that are exploiting different approaches to modulate the microbiome. Although fecal microbial transplants (FMTs) have been in practice for some time, the use of live biotherapeutic products (LBPs) in the form of single strains or microbial consortia is becoming a widely popular strategy due to targeted mechanisms and controlled production processes. The development of small molecule drugs (postbiotics) and use of phages are also being actively explored.
Currently, no microbiome therapeutic has been approved in the U.S. or in any other market. There are some candidates in Phase 3 trials, such as Seres Therapeutics SER109 and Rebiotix's RBX2660 that are being evaluated for the treatment of recurrent Clostridium difficile infection. Despite an expansive patent portfolio and a large number of clinical trials in the field of microbiome therapeutics, the market is facing some challenges.
The absence of any regulatory framework has created an uncertain situation for many developers in this novel market. The complexity of the human microbiome and variations among different individuals add to the difficulties in the design of clinical trials. Additionally, hurdles are expected during the scaling-up of processes and proving the functional aspects of these drugs.
For the microbiome therapeutics market to grow, a strong collaborative effort is needed from all stakeholders, including the regulatory agencies. Statistically relevant results and proof-of-concept studies driven by technological advances in biomarkers, functional assays, and computational biology are required that will eventually pave the way for product approvals.
The report includes:
An in-depth overview of the global microbiome therapeutics market
Analyses of the global market trends, with data corresponding to market size for 2021-2025, and projections of compound annual growth rates (CAGRs) through 2026
Latest information on market drivers and opportunities, challenges and restraints, technological developments, and regulatory updates, along with their impact on the stakeholders in this market
Evaluation of market potential for microbiome therapeutics market, their market share analysis on the basis of product types, applications, and regions
Highlights of this innovation driven microbiome therapeutics market covering current trends, disease areas of application, clinical trials and their stages, and new developments
Impact of COVID-19 pandemic on the global economy and delay in the clinical trial activity and financial effects on the overall growth of this market
Competitive landscape of this market featuring leading biopharmaceutical companies, their products pipeline and company share analysis
Key merger and acquisition deals, collaborations and partnerships, licensing and manufacturing agreements, and other notable investment strategies within this market
Patent review and deep-dive of the issued patents on the basis of categories such as type, year, disease type, company, country, and assignee
Profile description of the major market participants, including Azitra Inc., Evelo Biosciences, LNC Therapeutics, Second Genome and Vedanta Biosciences Inc.
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
The Human Microbiome
The Different Microbiomes in Humans
Microbiome and Human Health and Disease
Technologies Aiding Microbiome Research
Microbiome Research Projects
Microbiome Therapeutics
Strategies for Development of Microbiome Therapeutics
Microbiome Therapeutics Disease Areas
Regulatory Landscape for Microbiome Therapeutics
Chapter 4 Market Breakdown by Technology Type
Market by Microbiome Strategy Type
Market Overview
Additive Microbiome Therapeutics
Modulatory Microbiome Therapeutics
Subtractive Microbiome Therapeutics
Chapter 5 Market Breakdown by Application
Market by Disease Type
Market Overview
Market Revenue
Market Shares
Infections
Gastrointestinal (GIT) Diseases
Metabolic Diseases
Cancer
Gut-Brain Axis Diseases
Other Diseases
Market by Region
Market Shares
Chapter 6 Industry Structure
Investment in Microbiome Therapeutics
Public Funding Initiatives
Private Funding Initiatives
Collaborations and Partnerships
Licensing and Manufacturing Agreements
Mergers and Acquisitions
Leading Market Players in Microbiome Therapeutics Market
Select Insights from Industry Leaders
Chapter 7 Patent Analysis
Patent Analysis
Patents by Year
Patents by Type
Patents by Disease Type
Patents by Company
Patents by Country
Patents by Assignee
Chapter 8 Clinical Trial Analysis
Clinical Trial Analysis by Disease Category
Clinical Trial Analysis by Treatment Strategy
Clinical Trial Analysis by Company
Microbiome Therapeutics in Discovery and Preclinical Development
Microbiome Therapeutics Clinical Trials in Phase 3
Chapter 9 Analysis of Market Opportunities
SWOT Analysis
Strengths of Microbiome Therapeutics Market
Challenges for Microbiome Therapeutics Market
Opportunities for Microbiome Therapeutics Market
Threats to the Microbiome Therapeutics Market
Chapter 10 Company Profiles
4D Pharma
AO Biome LLC
Armata Pharmaceuticals
Assembly Biosciences Inc.
Azitra Inc.
Biomica
Biomx
Chain Biotechnology Ltd.
Eligo Bioscience SAS
Enterome SA
Evelo Biosciences
Finch Therapeutics Group Inc.
Intralytix Inc.
Kaleido Biosciences
Kintai Therapeutics Inc.
LNC Therapeutics Inc.
MaaT Pharma
Osel Inc.
Pylum Bioscienes Inc.
Quorum Innovations LLC
Rebiotix Inc. (Acquired by Ferring Pharmaceuticals)
The "Global Surgical Sutures Market: Focus on Applications, End Users, Products, Types and Over 14 Countries' Data - Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
This comprehensive report offers an...
The "Ginger Beer Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
The global ginger beer market has grown strongly in recent years. It will grow from $7.38 billion in 2023 to $7.94 billion in 2024 at a compound...
Pagaya Technologies Ltd. ("Pagaya", the "Company" or "we"), a global technology company delivering artificial intelligence infrastructure for the financial ecosystem, today announced that it filed its first annual report on Form 10-K for the year...
The Board of Directors of John Marshall Bancorp, Inc. (the "Company") declared an annual cash dividend of $0.25 per outstanding share of common stock on April 24, 2024, payable on July 8, 2024, to shareholders of record as of the close of business...
John Marshall Bancorp, Inc. (the "Company"), parent company of John Marshall Bank (the "Bank"), reported its financial results for the three months ended March 31, 2024.
Selected Highlights
Pristine Asset Quality ? For the eighteenth...
Today, Sensiva Health, which owns and operates a state-of-the-art molecular laboratory and ISO certified diagnostics manufacturing facility, announced their partnership with PointClickCare and has completed a full integration on the PCC marketplace....